Idorsia Wins FDA Breakthrough Status for Pediatric Insomnia
Allschwil, Switzerland, November 4, 2026 Idorsia Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted...
sleep disorders
Advertisement
Neurotronics Gains FDA Clearance for AI Sleep Analysis
Alachua, Florida, USA, November 3, 2026 Neurotronics, LLC, a Nihon Kohden company, has received U.S. Food and Drug Administration...
OncoC4 Receives FDA Fast Track for Cesalatamig
Rockville, Maryland, USA, September 16, 2026 OncoC4, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
Viatris WAKIX Approved in Japan for Sleep Disorders
Tokyo, Japan, September 16, 2026 Viatris Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved...
Takeda Wins Japan Approval for ORZEYFUL in Narcolepsy
OSAKA, Japan & CAMBRIDGE, Massachusetts, Aug 24, 2026 Takeda Pharmaceutical Company Limited announced that Japan’s Ministry of Health, Labour...
Advertisements
Harmony Biosciences Reports Record Q2 2026 Revenue, Shares Positive BP-205 Phase 1 Data
PLYMOUTH MEETING, Pa., August 4, 2026 Harmony Biosciences reported record second-quarter 2026 net revenue of $261.3 million for WAKIX®...
Jazz Presents New Xywav Data at SLEEP 2026 Meeting
DUBLIN, Ireland, June 16, 2026 Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new...
Takeda Oveporexton Shows Broad Benefits in Narcolepsy
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 15, 2026 Takeda has unveiled new pivotal Phase 3 data demonstrating that oveporexton...
Jazz Highlights New Xywav Data Across Narcolepsy and Idiopathic Hypersomnia
DUBLIN, Ireland, June 4, 2026 Jazz Pharmaceuticals has announced the presentation of an extensive portfolio of new clinical and...
Jazz Pharmaceuticals Presents Neurology Drug Data at AAN
DUBLIN, Ireland, April 9, 2026 Jazz Pharmaceuticals plc has announced the presentation of six scientific abstracts, including one oral...
Advertisement
